CCL

Összesen 5 találat.
#/oldal:
Részletezés:
Rendezés:

1.

001-es BibID:BIBFORM076403
035-os BibID:(cikkazonosító)8310583 (WOS)000456558900001 (Scopus)85060614324
Első szerző:Barta Zsolt (belgyógyász, gasztroenterológus)
Cím:Evaluation of objective signs and subjective symptoms of dry eye disease in patients with inflammatory bowel disease / Zsolt Barta, Levente Czompa, Aniko Rentka, Eva Zold, Judit Remenyik, Attila Biro, Rudolf Gesztelyi, Judit Zsuga, Peter Szodoray, Adam Kemeny-Beke
Dátum:2019
ISSN:2314-6133 2314-6141
Megjegyzések:Aim. To evaluate tear film parameters and relationship of objective clinical signs and subjective symptoms of dry eye disease (DED) in inflammatory bowel disease (IBD) subgroups. Methods. 39 patients with Crohn's disease (CD), 26 patients with ulcerative colitis (UC), and 39 control persons with no ocular symptoms or surface disorders were included in this prospective, case-control, and cross-sectional study. The ocular surface disease index (OSDI) questionnaire was applied to evaluate dry eye symptoms, and objective tests of DED were performed on both eyes of each subject. Results. The average of OSDI scores was 30.59 (+/- 16.68) in CD patients, 24.67 (+/- 23.48) in UC patients, and 11.19 (+/- 5.8) in controls. Except for tear film breakup time (tBUT) and Schirmer-I values other objective parameters were better in UC patients, than in CD patients. CD patients rather than UC patients tend to develop DED. This was associated with immunosuppressant and TNF- inhibitor use. Conclusions. Clinicians must be aware of the spectrum of DED involvement in IBD and suggest using artificial tears in order to decrease severity of ocular complications.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Inflammatory bowel diseases
Crohn's disease
Ulcerative colitis
Extraintestinal
Dry eye disease
Megjelenés:BioMed Research International. - 2019 (2019), p. 1-9. -
További szerzők:Czompa Levente (1981-) (arc-, állcsont- és szájsebész) Rentka Anikó (1986-) (szemész) Zöld Éva (1978-) (belgyógyász) Gálné Remenyik Judit (1965-) (kémia tanár, okleveles vegyész) Biró Attila (1988-) (okleveles biomérnök) Gesztelyi Rudolf (1969-) (kísérletes farmakológus) Zsuga Judit (1973-) (neurológus, pszichoterapeuta, egészségügyi szakmanager) Szodoray Péter (1973-) (belgyógyász, orvos) Kemény-Beke Ádám (1968-2021) (szemész)
Internet cím:Intézményi repozitóriumban (DEA) tárolt változat
DOI
Borító:

2.

001-es BibID:BIBFORM076676
035-os BibID:(cikkazonosító)8670398 (WOS)000458978300001 (Scopus)85062331886
Első szerző:Gergely Péter (igazságügyi orvosszakértő)
Cím:Tyrosine kinase inhibitor Imatinib mesylate alters DMBA-induced early onco/suppressor-gene expression with tissue-specificity in mice / Péter Attila Gergely, Balázs Murnyák, János Bencze, Andrea Kurucz, Timea Varjas, Katalin Gombos, Tibor Hortobágyi
Dátum:2019
ISSN:2314-6133 2314-6141
Megjegyzések:Tyrosine kinases play crucial roles in cellular development and tumorigenesis. Tyrosine kinase inhibitors (TKIs) are effective and widely-used drug molecules in targeted cancer therapies. Altered expressions of proto-oncogenes and tumor suppressor genes after DMBA (7,12- dimethylbenz[a]anthracene) treatment have been described as early markers of tumor induction, however their tissue-specific effects remain still unclear. Our study was aimed to examine the short-term possible anti-neoplastic and chemo-preventive effects of a TKI compound (imatinib mesylate) on a DMBA-induced mouse tumor model. In addition, we also investigated the tissue specific expressions of Hras, Kras, Myc, Trp53 genes in the brain, bone marrow, spleen, liver, abdominal lymph nodes, thymus, lungs and kidneys, respectively. 24 hours after the imatinib mesylate injection, we observed significant Kras down-regulations in the bone marrow and lung of the DMBA-treated mice. Moreover, the mRNA expression of Myc was also found to be decreased significantly in the spleen. Interestingly, while Trp53 expression was significantly increased in the lung, it was decreased in the other tissues. However, there was also a tendency in the decreased Myc level in the bone marrow, brain, kidneys, lungs, lymph nodes, and in the decreased Hras level in the bone marrow, kidneys and lungs, although no significant differences were observed. Our findings indicate rapid tissue-specific impact of imatinib mesylate on DMBA-induced gene expression in vivo, supporting the chemo-preventive potential of imatinib mesylate in cancer.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:BioMed Research International. - 2019 (2019), p. 1-12. -
További szerzők:Murnyák Balázs (1986-) (molekuláris biológus, genetikus) Bencze János (1991-) (orvos) Kurucz Andrea (1984-) (orvos) Varjas Tímea Gombos Katalin Hortobágyi Tibor (1965-) (patológus)
Pályázati támogatás:2017-1.2.1-NKP-2017-00002
Egyéb
UNKP-18-3
Egyéb
EFOP-3.6.3-VEKOP-16-2017-00009
EFOP
Internet cím:DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

3.

001-es BibID:BIBFORM079346
035-os BibID:(cikkazonosító)7213913 (WOS)000464702500001 (Scopus)85065782402
Első szerző:Kiss Rita (laboratóriumi diagnosztika szakorvos)
Cím:Diosgenin and Its Fenugreek Based Biological Matrix Affect Insulin Resistance and Anabolic Hormones in a Rat Based Insulin Resistance Model / Kiss Rita, Pesti-Asbóth Georgina, Szarvas Mária Magdolna, Stündl László, Cziáky Zoltán, Hegedűs Csaba, Kovács Diána, Badale Andrea, Máthé Endre, Szilvássy Zoltán, Remenyik Judit
Dátum:2019
ISSN:2314-6133 2314-6141
Megjegyzések:Fenugreek is known since ancient times as a traditional herbal medicine of its multiple beneficial effects. Fenugreek's most studied and employed effect is its hypoglycemic property, but it can also be useful for the treatment of certain thyroid disorders or for the treatment of anorexia. The regulation of glucose homeostasis is a complex mechanism, dependent on the interaction of different types of hormones and neurotransmitters or other compounds. For the study of how diosgenin and fenugreek seeds modify insulin sensitivity, we used a rat insulin resistance model induced by high-fat diet. Diosgenin in three different doses (1mg/bwkg, 10mg/bwkg, and 50mg/bwkg, respectively) and fenugreek seed (0.2 g/bwkg)were administered orally for 6weeks. Insulin sensitivity was determined by hyperinsulinemic euglycemic glucose clamp method. Our research group found that although glucose infusion rate was not significantly modified in either group, the increased insulin sensitivity index and high metabolic clearance rate of insulin found in the 1 mg/kg diosgenin and the fenugreek seed treated group suggested an improved peripheral insulin sensitivity. Results from the 10 mg/kg diosgenin group, however, suggest a marked insulin resistance. Fenugreek seed therapy results on the investigated anabolic hormones support the theory that, besides insulin and gastrointestinal peptides, the hypothalamichypopituitary axis regulated hormones synchronized action with IGF-1 also play an important role in the maintaining of normal glucose levels. Both diosgenin and fenugreek seeds are capable of interacting with substrates of the above-mentioned regulatory mechanisms, inducing serious hormonal disorders. Moreover, fenugreek seeds showed the ability to reduce the thyroid hormone levels at the periphery and to modify the T4/T3 ratio. It means that in healthy people this effect could be considered a severe side effect; however, in hypothyroidism this effect represents a possibility of alternative natural therapy.
Tárgyszavak:Agrártudományok Élelmiszertudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Diosgenin
Fenugreek
Insulin Resistance
Anabolic Hormones
Rat
Megjelenés:Biomed Research International. - 2019 (2019), p. 1-13. -
További szerzők:Pesti-Asbóth Georgina (1990-) (élelmiszerbiztonsági és -minőségi mérnök) Szarvas Mária Magdolna (1989-) (élelmiszeripari mérnök) Stündl László (1970-) (agrármérnök) Cziáky Zoltán Hegedűs Csaba (1983-) (Molekuláris biológus, Cera-Med Kft. Debrecen) Kovács Diána Klára (1985-) (Molekuláris biológus) Badale, Andrea (1986-) (gyógyszerész) Máthé Endre (1964-) (genetikus, molekuláris sejtbiológus) Szilvássy Zoltán (1957-) (belgyógyász, farmakológus, klinikai farmakológus) Gálné Remenyik Judit (1965-) (kémia tanár, okleveles vegyész)
Pályázati támogatás:EFOP-3.6.2-16-2017-00009
EFOP
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

4.

001-es BibID:BIBFORM072121
035-os BibID:(cikkazonosító)7212861 (WOS)000423801800001 (Scopus)85052150790
Első szerző:Kurucz Andrea (orvos)
Cím:Heme oxygenase-1 activity as a correlate to exercise-mediated amelioration of cognitive decline and neuropathological alterations in an aging rat model of dementia / Kurucz A., Bombicz M., Kiss R., Priksz D., Varga B., Hortobágyi T., Trencsényi G., Szabó R., Pósa A., Gesztelyi R., Szilvássy Z., Juhász B.
Dátum:2018
ISSN:2314-6133 2314-6141
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Megjelenés:Biomed Research International. - 2018 (2018), p. 1-13. -
További szerzők:Bombicz Mariann (1987-) (gyógyszerész) Kiss Rita (1974-) (laboratóriumi diagnosztika szakorvos) Priksz Dániel (1989-) (farmakológus) Varga Balázs (1984-) (kísérletes farmakológus) Hortobágyi Tibor (1965-) (patológus) Trencsényi György (1978-) (biológus, biokémikus, molekuláris biológus) Szabó Renáta Pósa Anikó Gesztelyi Rudolf (1969-) (kísérletes farmakológus) Szilvássy Zoltán (1957-) (belgyógyász, farmakológus, klinikai farmakológus) Juhász Béla (szülész-nőgyógyász)
Internet cím:DOI
Szerző által megadott URL
Intézményi repozitóriumban (DEA) tárolt változat
Borító:

5.

001-es BibID:BIBFORM081263
035-os BibID:(cikkazonosító)2510875 (WOS)000492956900004 (Scopus)85068695791
Első szerző:Zaha, Dana Carmen
Cím:Recent Advances in Investigation, Prevention, and Management of Healthcare-Associated Infections (HAIs) : resistant Multidrug Strain Colonization and Its Risk Factors in an Intensive Care Unit of a University Hospital / Dana Carmen Zaha, Rita Kiss, Csaba Hegedűs, Rudolf Gesztelyi, Mariann Bombicz, Mariana Muresan, Annamaria Pallag, Miklos Zrinyi, Denes Pall, Cosmin Mihai Vesa, Otilia Micle
Dátum:2019
ISSN:2314-6133 2314-6141
Megjegyzések:Active screening for resistant multidrug strain carriers remains an important component of infection control policy in any healthcare setting indifferent of financial and logistical costs.The objective of our study was to determine the spectrum of bacterial colonization individually among intensive care unit patients. A retrospective observational study was performed in the Intensive CareUnit of Emergency Clinical CountyHospital of Oradea during 2017.Medical records of the patients were used for evaluation of source of ICU admission, previous antibiotic therapy, comorbidities, and length of hospital stay. Nasal and groin swabs for MRSA detection and rectal swabs for ESBL, VRE, and CRE detection were collected upon ICU admission of all patients in the first 24 hours and after 7 days. Swab samples were processed for isolation and identification of these resistant multidrug strains. Bacterial colonization on admission was detected in a quarter of patients included in the study. Carbapenemase-producing bacteria were the most common colonizers (21.16%). On admission, 12.06% of patients have been colonized by ESBL-producing members of the family Enterobacterales. Risk factors for colonization on admission to the ICU were chronic liver diseases and chronic renal failure for ESBL infection and chronic liver disease for CRE in male patients. Evaluation of Carmeli's score for male patients showed association only with CRE colonization. Chronic renal failure was found as risk factor for ESBL colonization in female patients. The prevalence of MRSA was 5.23% and less than 1% for VRE.There was no association between any risk factors studied and the presence of S. aureus or VRE upon admission. The 7-day ICU stay also proved to be an increased risk for ESBL and CRE infection.
Tárgyszavak:Orvostudományok Klinikai orvostudományok idegen nyelvű folyóiratközlemény külföldi lapban
folyóiratcikk
Intensive Care Unit
Healthcare-Associated Infections
Megjelenés:Biomed Research International. - 2019 (2019), p. 1-9. -
További szerzők:Kiss Rita (1974-) (laboratóriumi diagnosztika szakorvos) Hegedűs Csaba (1983-) (Molekuláris biológus, Cera-Med Kft. Debrecen) Gesztelyi Rudolf (1969-) (kísérletes farmakológus) Bombicz Mariann (1987-) (gyógyszerész) Muresan, Mariana Pallag Annamária Zrínyi Miklós (kémikus) Páll Dénes (1967-) (belgyógyász, kardiológus) Vesa, Cosmin Mihai Micle, Otilia
Pályázati támogatás:EFOP-3.6.2-16-2017-00009
EFOP
Internet cím:Szerző által megadott URL
DOI
Intézményi repozitóriumban (DEA) tárolt változat
Borító:
Rekordok letöltése1